Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

By Luc F Van Gaal, A. Rissanen, A. Scheen, O. Ziegler, S. Rössner. The Lancet, 2005

1,527 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Non-alcoholic fatty liver disease: the mist gradually clears. (2008, background): “The cannabinoid receptor 1 (CB1) antagonist rimonabant has been shown to be effective in reducing weight and waist circumference, with improvements in several metabolic parameters including insulin resistance [62].”
The metabolic syndrome. (2003, positive): “Both the Rimonabant in Obesity-Europe study [61] and the Rimonabant in Obesity-North America study [62] showed that rimonabant induces significant weight loss that can be sustained over a 2-year period.”
Cannabinoid pharmacology: the first 66 years (2006, background): “Indeed, SR141716A (rimonabant) will most likely soon be licensed for use as an antiobesity agent (Van Gaal et al., 2005).”
The Endocannabinoid System as an Emerging Target of Pharmacotherapy (2006, background): “…rimonabant for nicotine cessation or for the treatment of obesity, diarrhea was 2 to 2.4 times more frequent among subjects treated with the drug than with placebo, suggesting accelerated transit and/or enhanced secretion caused by CB1 blockade (Fernandez and Allison, 2004; Van Gaal et al., 2005).”
Activation of the peripheral endocannabinoid system in human obesity. (2005, background): “Rimonabant has been tested successfully in phase III trials as an adjunctive obesity treatment (19,20).”